Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the efficacy and safety of co-administration of DWC202206 and DWC202207 in patients with concomitant hypertension and hyperlipidemia.
The study design is a randomized, double-blind, multicenter clinical trial. The patients were randomly assigned to each group. Primary endpoint was the change of MSSBP based on baseline between Treatment arm and control 1 arm and the change of LDL-C based on baseline between arm and control 2 arm.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| (D) DWC202206 + DWC202207 | Experimental |
| |
| (P+D) DWC202206 + DWC202207 | Active Comparator |
| |
| (D+P) DWC202206 + DWC202207 | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| (D) DWC202206 | Drug | Drug of DWC202206 A mg |
|
| Measure | Description | Time Frame |
|---|---|---|
| The change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline between treatment arm and control 1 arm | 8 weeks | |
| The change of LDL-C based on baseline between treatment arm and control 2 arm | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| The change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline between treatment arm and control 1 arm | 4 weeks | |
| The change of LDL-C based on baseline between treatment arm and control 2 arm | 4 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kangbuk Samsung Hospital | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
| (D) DWC202207 | Drug | Drug of DWC202207 B/C mg |
|
| (P) DWC202206 | Drug | Placebo of DWC202206 A mg |
|
| (P) DWC202207 | Drug | Placebo of DWC202207 B/C mg |
|
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D006949 | Hyperlipidemias |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C007792 | Fumigant 93 |
Not provided
Not provided
Not provided